

#### (43) International Publication Date 25 April 2002 (25.04.2002)

PCT

(10) International Publication Number

(51) International Patent Classification7: 30/08, 26/00, A61K 31/74

C08F 20/00.

English

WO 02/032974 A3

(21) International Application Number: PCT/JP01/07958

Yoshimitsu [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). SAWADA, Hideo [JP/JP]; 572-7, Yao, Tawaramotocho, Shiki-gun, Nara 636-0311 (JP).

(22) International Filing Date: 13 September 2001 (13.09.2001) (74) Agent: NOGAWA, Shintaro; MINAMIMORIMACHI PARK BLDG., 1-3. Nishitenma 5-chome, Kita-ku, Osaka-shi, Osaka 530-0047 (JP).

(25) Filing Language:

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, English CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,

ZW.

(26) Publication Language:

(30) Priority Data:

PR0850 18 October 2000 (18.10.2000) AU PR3754 15 March 2001 (15.03.2001) PR7382 30 August 2001 (30.08.2001) AU

> (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK,

SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,

(71) Applicant (for all designated States except US): FUJI-SAWA PHARMACEUTICAL CO., LTD. [JP/JP]: 4-7. Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

#### Published:

with international search report

(72) Inventors; and (75) Inventors/Applicants (for US only): YAMADA, Akira [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP), SHIMAZAKL Norihiko [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome. Chuo-ku, Osaka-shi, Osaka 541-8514 (JP), NAKAYAMA, Osamu [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). SHOBO, Miwako [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP), NAKAJIMA, ning of each regular issue of the PCT Gazette,

(88) Date of publication of the international search report: 20 February 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the begin-

(54) Title: POLYMER AND ITS USE FOR THE TREATMENT AND/OR PREVENTION OF HYPERPHOSPHOREMIA

$$H_2C = C$$
 $R^2$ 
 $R^3$ 

$$R^2$$

$$R^3$$

$$H_2C=C$$
(II)

(57) Abstract: A polymer or its salt which is obtainable by polymerization of a monomer of the formula (I) or its salt in the presence of a radical initiator, or by polymerization of a monomer of the formula (1) or its salt with a monomer of the formula (II) or its salt in a molar ratio of (I): (II) being 1:0.1 to 1:25 in the presence of a radical initiatorwherein R1 and R3 are each hydrogen atom or lower alkyl group, R2 and R4 are each acvl group, aliphatic silvl group, amino lower alkyl group which may have one or more suitable substituent(s),heterocyclic group which may have one or more suitable substituent(s) orcarboxy group esterified by the residue of cellulose optionally substituted with one or more lower alkyl and/or lower alkenovl.

## INTERNATIONAL SEARCH REPORT

Into al Application No PCT/JP 01/07958

1PC 7	FICATION OF SUBJECT MATTER COSF20/00 COSF30/08 COSF26/	/00 A61K31/74							
According to International Petent Classification (IPC) or to both national classification and IPC									
B. FIELDS SEARCHED									
Militrate commentation searched (classification system followed by classification symbols)  IPC 7 C08F A61K									
Documentation searched other than minimum decumentation to the extent that such documents are included in the liabits searched									
Executants data base consulted during the International search (name of data base and, whom practical, courch turms used)  EPO-Internal, WPI Data, PAJ, COMPENDEX, CHEM ABS Data									
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT								
Category *	Citation of document, with indication, where appropriate, of the re-	levant passages	Relevant to claim No.						
х	WO 95 05184 A (GELTEX PHARMA INC 23 February 1995 (1995-02-23) the whole document	;) 	1-8, 10-16						
Furt	er documents are listed in the continuation of box C.	X Patent family members are listed in	annex.						
"A" docume consider the consider of the consider of the constance of the c	It which may throw doubte on priority clasings) or cried to establish the publication dute of another or other special reason (as specified) in tradering to an oral disclosure, use, exhibition or sears to published prior to the international filing date but an the priority date claimed	"These decounterposition of parts to international lift of other or printing that are not in conduct without population that on printing that was not in conduct with the population that one of the printing that the printing or theory underlying to the conduction of the printing that the printing that the printing that the conduction of the conduction o							
	Date of the natural completion of the international search  Determine of mailing of the international search  14, 08, 2002								
19 April 2002									
Name and m	alling address of the ISA European Patent Office, P.B. 5818 Patentlean 2 NL - 2280 HV Rilewijk Tal. (+31-70) 340-340, Tx. 31 651 epo nl, Fax: (+81-70) 340-3016.	Authorized officer Pollio, N							

# INTERNATIONAL SEARCH REPORT

ational appli	cation No.
	01/07958

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	mational Search Report has not been established in resport of certain claims under Article 17(2)(a) for the following reasons:
1. 🗌	Claims No.: , because they relate to subject matter not required to be searched by this Authority, namely:
2. <u> </u>	Claims Nos.: because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be earlied out, specifically:
з. 🗌	Cilairne Nos.: because they are dependent claims and are not drefted in accordance with the second and third sentences of Rule 8.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This inte	mational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1.	As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority cld not invite payment of any additional fee.
а. 🗌	As only some of the required additional search frees were timely paid by the applicant, this international Search Report covers crity those claims for which fees were paid, specifically claims Nos.
4. X	No required additional search fees were timely paid by the applicant. Consequently, this informational Search Report is restricted to the invention first mentioned in the dalms; it is covered by claims Nos.: $1,5-6,9-16$
	on Protest  The additional search fees were accompanied by the applicant's protest.
rvemark	on Protest The additional search tees were accomparised by tine applicant's protest:  No protest accompanied the payment of additional search fees.
	The second secon

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 218

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

#### 1. Claims: [1], [5-6], [9-16]

A polymer or its salt which is obtainable by polymerization of a monomer of the formula I (as reported in claim I of the present application) or its salt in the presence of a radical initiator wherein RI is hydrogen or lower alkyl group which may have one or more suitable substituent(s); a polymer obtained by polymerization of a monomer of the formula I or its salt with a monomer of fromula II or its salt with a monomer of fromula II or its salt in a molar ration of I to II being 1:8.1 to 1:25 in the presence of a radical initiator, wherein each RI and R3 are indipendently hydrogen and / or lower alkyl group, each R2 and R4 are an amino lower alkyl group which may have one or more suitable substituent(s). A pharmaceutical composition comprising the polymer and its use in the treatment / prevention of hyperhosphoremia.

#### 2. Claims: [1-16]

A polymer or its salt obtained by polymerization of a monomer of the formula I or its salt with a monomer of formula II or its salt in a molar ration of I to II being 1:0.1 to 1:25 in the presence of a radical initiator, wherein each Rl and R3 are indipendently hydrogen and / or lower alkyl group, one of R2 or R4 is an amino lower alkyl group which may have one or more suitable substituent(s) the other is an acyl or a carboxy group esterified by the residue of cellulose optionally substitued with one or mor lower alkyl and / or lower alkyl and / or lower alkenoyl. A pharmaceutical composition comprising the polymer and its use in the treatment / prevention of hyperhosphoremia.

## 3. Claims: [1], [5-6], [9-16]

A polymer polymerization of a monomer of the formula I or its salt with a monomer of formula I or its salt in a molar ration of I to II being 1:0.1 to 1:25 in the presence of a radical initiator, wherein each RI and R3 are indipendently hydrogen and / or lower alkyl group, one of R2 or R4 is an amino lower alkyl group which may have one or more suitable substituent(s) the other a siyl group. A pharmaceutical composition comprising the polymer and its use in the treatment / prevention of hyperphosphoremia.

## 4. Claims: [1], [5-6], [9-16]

A polymer or its salt which is obtainable by polymerization of a monomer of the formula I or its salt with a monomer of

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 218

formula II or its salt in a molar ration of 1 to II being 11.0.1 to 11.25 in the presence of a radical initiator, wherein each RI and R3 are indipendently hydrogen and / or lower alkyl group, one of R2 or R4 is an amino lower alkyl group which may have one or more suitable substituent(s) the other a heterocyclic group. A pharmaceutical composition comprising the polymer and its use in the treatment / prevention of hyperphosphoremia.

## 5. Claims: [1-16]

A polymer or its salt which is obtainable by polymerization of a monomer of the formula I (as reported in claim I of the present application) or its salt in the presence of a radical initiator; or by polymerization of a monomer of the formula I or its salt with a monomer of formula II or its salt in a molar ration of I to II being 1:0.1 to 1:25 in the presence of a radical initiator, wherein each RI and R3 are indipendently hydrogen and / or lower alkyl group, each R2 and R4 are indipendently an acyl and / or a carboxy group esterified by the residue of cellulose (optionally substitued with one or more lower alkyl and / or lower alkenoyl) and / or an heterocyclic group and / or a silyl group. A pharmaceutical composition comprising the polymer and its use in the treatment / prevention of

#### 6. Claims: [12-16]

A (homo)polymer or its salt which is obtainable by polymerlzation of a monomer of the formula I (as reported in claim I of the present application) or its salt in the presence of a radical initiator wherein RI is hydrogen or lower alkyl group and RA is aryl group. A pharmaceutical composition comprising the polymer and its use in the treatment / prevention of hydernhosshoremia.

page 2 of 2

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Int nat Application No PCT/JP 01/07958

				1.01/01	01,0,500
Patent doc cited in sean	ument ch report	Publication date		Patent family member(s)	Publication date
WO 9505	184 A	23-02-1995	US AT AU CA CA DE DE DE DE DE DE DE DE DE DE DE DE DE	5496545 A 204756 T 689797 B2 7566797 B2 7566794 A 2169256 A1 2319260 A1 63428122 D1 69428122 D1 71,6666 T3 71,6666 A1 2161780 T3 2131328 B2 2001055336 A 90884 A9 271626 T 9565184 A2 56677775 A 6083495 A	05-03-1996 15-09-2001 09-09-2001 19-09-1998 14-03-1995 12-02-1995 04-10-2001 18-04-2002 17-12-2001 19-05-2001 19-05-2001 19-05-2001 19-05-2001 19-05-2001 19-05-2001 19-05-2001 19-05-2001 27-11-2000 27-05-2001 28-06-2002 23-06-2002 23-06-2002 23-06-2002 23-06-2002 23-06-2002
1					